

**PATIENT INFORMATION LEAFLET**  
**MYALICA RANGE**

**SCHEDULING STATUS**

S5

**MYALICA 25 mg capsules**

**MYALICA 75 mg capsules**

**MYALICA 150 mg capsules**

Pregabalin

MYALICA is sugar free.

**Read all of this leaflet carefully before you start taking MYALICA**

- Keep this leaflet. You may need to read it again.
- If you have further questions, please ask your doctor, pharmacist, nurse or other healthcare provider.
- MYALICA has been prescribed for you personally and you should not share your medicine with other people. It may harm them, even if their symptoms are the same as yours.

**What is in this leaflet**

1. What MYALICA is and what it is used for
2. What you need to know before you take MYALICA
3. How to take MYALICA
4. Possible side effects
5. How to store MYALICA
6. Contents of the pack and other information

## PATIENT INFORMATION LEAFLET

### MYALICA RANGE

#### 1. What MYALICA is and what it is used for

MYALICA is used to treat peripheral neuropathic pain (long-lasting pain caused by damage to the nerves), due to diabetes or shingles in adults.

#### 2. What you need to know before you take MYALICA

##### Do not take MYALICA:

- if you are allergic (hypersensitive) to pregabalin or any of the other ingredients of MYALICA (listed in section 6).

##### Warnings and precautions

##### Take special care with MYALICA:

- if you have diabetes and gain weight while you are taking MYALICA, your doctor may need to make a change in your diabetic medicines
- if you experience an allergic reaction while you are taking MYALICA, you must contact your doctor immediately. The symptoms of an allergic reaction include swelling of the face, lips, tongue, and throat, as well as a skin rash
- if you take MYALICA you may experience dizziness, sleepiness, loss of consciousness, confusion, and mental impairment. This could increase the possibility of an accidental injury (fall) if you are an elderly patient. Therefore, you should be careful until you are used to any effect caused by MYALICA
- if you take MYALICA you may experience blurring or loss of vision, or other changes in eyesight, many of which are temporary. You should immediately tell your doctor if you experience any changes in your vision
- if you notice a decrease in passing urine while taking MYALICA, you should tell your doctor. It may improve if you stop taking MYALICA

## PATIENT INFORMATION LEAFLET

### MYALICA RANGE

- if you are taking MYALICA, or shortly after stopping it, you may experience convulsions (including epilepsy). If this happens, contact your doctor immediately. You may also experience withdrawal symptoms after short-term or long-term treatment with MYALICA, which include difficulty in sleeping, headache, nausea, anxiety, diarrhoea, flu syndrome, nervousness, depression, pain, hyperhidrosis and dizziness
- if you have a history of a heart disease you should tell your doctor. Heart failure has been reported in some patients when they were taking MYALICA
- if you are taking medicines for spinal cord injury, you may experience an increase in certain side effects such as sleepiness, when you are also taking MYALICA
- some people have had thoughts to harm or kill themselves while taking medicines belonging to the same group as MYALICA for the treatment of different conditions. If you have thoughts of harming or killing yourself, at any time when you are taking MYALICA, immediately contact your doctor
- when MYALICA is taken with other medicines that may cause constipation (such as some types of pain medicines) it is possible that gastrointestinal problems may occur (e.g. constipation, blocked or paralysed bowel). Tell your doctor if you experience constipation, especially if you are prone to this problem
- if you have a history of alcoholism or substance abuse or dependence, you should tell your doctor. If you think you need more MYALICA than prescribed, tell your doctor
- if you have a history of any serious medical conditions you should tell your doctor. There have been reports of reduction in brain function (encephalopathy) in some patients when they were taking MYALICA.

If you are not sure whether any of the above applies to you, ask your pharmacist – or your doctor.

**PATIENT INFORMATION LEAFLET**  
**MYALICA RANGE**

**Other medicines and MYALICA**

Always tell your healthcare provider if you are taking any other medicine. (This includes all complementary or traditional medicines.)

MYALICA and certain other medicines may influence each other (interaction). When taken with certain other medicines, MYALICA may potentiate the side effects seen with these medicines, including respiratory failure and coma. The degree of dizziness, sleepiness and decreased concentration may be increased if MYALICA is taken together with medicines containing:

- Oxycodone (for treatment of pain)
- Lorazepam (for treatment of anxiety)
- Alcohol.

MYALICA may be taken with oral contraceptives.

**MYALICA with food and drink**

MYALICA may be taken with or without food.

It is advised not to drink alcohol while you are taking MYALICA.

**Pregnancy, breastfeeding and fertility**

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking MYALICA.

MYALICA should not be taken during pregnancy or when breastfeeding. Effective contraception must be used by women of child-bearing potential.

**PATIENT INFORMATION LEAFLET**  
**MYALICA RANGE**

**Driving and using machines**

MYALICA may cause dizziness, sleepiness and decreased concentration. Head and body injuries and road traffic incidents have also been reported with MYALICA. You should not drive, operate machinery or engage in other potentially hazardous activities until you know whether MYALICA affects your ability to perform these activities.

**3. How to take MYALICA**

Do not share medicines prescribed for you with any other person.

Always take MYALICA exactly as your doctor has told you. Check with your doctor if you are not sure.

Your doctor will determine what dose is appropriate for you.

**The usual dose is:** 75 mg twice daily, (150 mg/day), with or without food. Based on individual patient response and tolerability, the dose may be increased to 150 mg twice daily after an interval of 3 to 7 days.

MYALICA is a long-term treatment and you may need to take it for some time. Your doctor will tell you how long your treatment with MYALICA will last.

MYALICA is for oral use only. MYALICA is taken orally with or without food. Swallow the capsule whole with water.

If you have the impression that the effect of MYALICA is too strong or too weak, tell your doctor or pharmacist.

**PATIENT INFORMATION LEAFLET**  
**MYALICA RANGE**

***Children and adolescents***

The safety and efficacy in children and adolescents (under 18 years of age) has not been established and therefore MYALICA should not be given to patients in this age group.

***Kidney disorders***

Your doctor may prescribe a different dosing schedule and/or dose.

***Elderly patients***

If you are an elderly patient (over 65 years of age), you should take MYALICA normally except if you have problems with your kidneys. Discuss with your doctor.

**If you take more MYALICA than you should**

In the event of overdosage, consult your doctor or pharmacist, if neither is available, contact the nearest hospital or poison centre. You may feel sleepy, confused, agitated, or restless as a result of taking more MYALICA than you should. Fits have also been reported.

**If you forget to take MYALICA**

It is important to take your MYALICA capsules regularly at the same time each day. If you forget to take a dose, take it as soon as you remember, unless it is time for your next dose. In that case, just carry on with the next dose as normal. Do not take a double dose to make up for forgotten individual doses.

**Effects when treatment with MYALICA is stopped**

Do not stop taking MYALICA unless your doctor tells you to. If your treatment is stopped it should be done gradually over a minimum of one week.

**PATIENT INFORMATION LEAFLET**  
**MYALICA RANGE**

#### **4. Possible side effects**

MYALICA can have side effects.

Not all side effects reported for MYALICA are included in this leaflet. Should your general health worsen or if you experience any untoward effects while taking MYALICA, please consult your doctor, pharmacist or other healthcare provider for advice.

If any of the following happens, stop taking MYALICA and tell your doctor immediately or go to the casualty department at your nearest hospital:

- swelling of the hands, feet, ankles, face, lips and mouth or throat, which may cause difficulty in swallowing or breathing
- rash or itching.

These are all very serious side effects. If you have them, you may have had a serious reaction to MYALICA. You may need urgent medical attention or hospitalisation.

Tell your doctor immediately or go to the casualty department at your nearest hospital if you notice any of the following:

- heart disorders including heart failure, heart rhythm disturbances, such as increased heart rate, irregular heartbeat
- an extremely severe skin reaction with rash, ulcers or blisters on the skin (Stevens-Johnson syndrome)
- inflammation of the eyes (keratitis)
- urinary incontinence, difficulty in passing urine, kidney failure, passing small amounts of urine, urinary retention
- inflammation of the liver (hepatitis)
- yellowing of the skin and eyes (jaundice).

**PATIENT INFORMATION LEAFLET**  
**MYALICA RANGE**

These are all serious side effects. You may need urgent medical attention.

Tell your doctor if you notice any of the following:

*Frequent:*

- inflammation of nasal passages (common cold)
- increased appetite
- feeling of elation, confusion, irritability, disorientation, sleeplessness, and changes in sexual interest
- dizziness, sleepiness, headache
- clumsiness, tremor, difficulty with speaking, forgetfulness, loss of memory, disturbance in attention, numbness or 'pins and needles', abnormally decreased sensitivity to stimulation
- sedation, abnormal style of walking (balance disorder), lack of energy
- blurred vision, double vision
- sensation of movement
- vomiting, nausea, constipation, diarrhoea, feeling bloated, abdominal distension, dry mouth
- muscle cramp, pain in a joint, back pain, pain in a limb, cervical spasm
- difficulties with erection
- swelling of feet and lower legs caused by fluid retention, abnormal manner of walking, falling, feeling drunk, abnormal feeling, tiredness
- weight gain.

*Less frequent:*

- reduced numbers of white blood cells which may make you more likely to get



## PATIENT INFORMATION LEAFLET

### MYALICA RANGE

infections (neutropenia)

- loss of appetite, low blood sugar
- seeing or hearing things that are not there, panic attacks, restlessness, exceeding restlessness, depression, depressed mood, elevated mood, aggression, mood swings, change in perception of self (depersonalisation), difficulty speaking, abnormal dreams, lack of feeling or emotion, loss of inhibition
- fainting, numbness, contraction of a muscle, loss of consciousness, jerky movements, difficulty of movement, dizziness on standing, tremor on movement, unusual eye movement, decreased consciousness, difficulty with thinking, speech disorder, reduced reflexes, increased sensitiveness of the skin, burning sensation, loss of taste, feeling of bodily discomfort, convulsions, perversion of the sense of smell, partial or complete loss of muscle movement, inability to write coherently, as a symptom of brain disease or damage
- vision loss, peripheral vision loss, visual disturbance, eye swelling, visual field defect, reduced visual sharpness, eye pain, eye condition that manifests itself through nonspecific symptoms such as fatigue, pain in or around the eyes, the presence of flashes of light, dry eye, watery eyes, eye irritation
- visual field disturbance, altered visual depth perception, abnormal dilation of the pupil, squinting of eye(s), visual brightness
- increased sensitivity to sound
- low blood pressure, high blood pressure, hot flushes, redness of the neck and face, feeling cold
- shortness of breath, nosebleed, cough, blocked nose, runny nose, snoring, nasal dryness, fluid in the lungs, tightness of the throat
- heartburn, increased saliva production, numbness around the mouth, abdominal

## PATIENT INFORMATION LEAFLET

### MYALICA RANGE

swelling, inflammation of the pancreas, swollen tongue, difficulty in swallowing

- hives, excessive sweating, itching of the skin, cold sweat
- joint swelling, pain in a muscle or muscles, muscle twitching, neck pain, muscle stiffness, breakdown of muscle tissue
- problems with sexual functioning including inability to achieve a sexual climax, increased libido, difficulties with erection, delayed ejaculation, painful menstrual periods, breast pain, absence of menstrual period, breast discharge, breast enlargement, breast enlargement in men
- generalised swelling caused by fluid retention, swelling of the face, chest tightness, pain, fever, thirst, chills, weakness
- changes in blood and liver test results (increased blood creatinine phosphokinase, increased alanine amino transferase, increased blood glucose, increased aspartate aminotransferase, decreased platelet count, increased blood creatinine, decreased blood potassium, decreased white blood cell count.

#### *Unknown frequency:*

- thoughts of harming or killing one-self.

If you notice any side effects not mentioned in this leaflet, please inform your doctor or pharmacist.

#### **Reporting of side effects**

If you get side effects, talk to your doctor, pharmacist or nurse.

You can also report side effects to SAHPRA via the “6.04 Adverse Drug Reaction Reporting

**PATIENT INFORMATION LEAFLET**  
**MYALICA RANGE**

Form”, found online under SAHPRA’s publications:

<https://www.sahpra.org.za/Publications/Index/8>.

By reporting side effects, you can help provide more information on the safety of MYALICA.

## **5. How to store MYALICA**

Store all medicines out of reach of children.

Store at or below 25 °C.

Protect from light and moisture.

Keep the container tightly closed.

Do not use after the expiry date stated on the carton.

Return all unused medicine to your pharmacist.

Do not dispose of unused medicine in drains or sewerage systems (e.g. toilets).

## **6. Contents of the pack and other information**

### **What MYALICA contains**

MYALICA 25 mg: Each capsule contains 25 mg pregabalin.

MYALICA 75 mg: Each capsule contains 75 mg pregabalin.

MYALICA 150 mg: Each capsule contains 150 mg pregabalin.

### **The other ingredients are:**

Isopropyl alcohol, pregelatinised starch, purified water, talc.

### ***Composition of gelatin capsule shell:***

Gelatin, iron oxide red (75 mg strength), purified water, sodium lauryl sulphate, titanium dioxide.

### ***Composition of imprinting ink on gelatin capsule:***

## **PATIENT INFORMATION LEAFLET**

### **MYALICA RANGE**

Black iron oxide, butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac, strong ammonia solution.

#### **What MYALICA looks like and contents of the pack**

MYALICA 25 mg: Size '4' capsules with white cap and white body, imprinted with "PG" on cap and "25" on body in black ink, containing white to off-white powder.

MYALICA 75 mg: Size '4' capsules with dark brown cap and white body, imprinted with "PG" on cap and "75" on body in black ink, containing white to off-white powder.

MYALICA 150 mg: Size '2' capsules with white cap and white body, imprinted with "PG" on cap and "150" on body in black ink, containing white to off-white powder.

#### **Contents of the pack**

Clear, transparent PVC/aluminium blister strips packed inside an outer carton. Each pack contains 56 capsules in four blister strips of 14 capsules.

#### **7. Holder of Certificate of Registration**

Pharma Dynamics (Pty) Ltd

1<sup>st</sup> Floor, Grapevine House, Steenberg Office Park

Silverwood Close

Westlake, Cape Town

7945, South Africa

Tel: + 27 21 707 7000

#### **8. This leaflet was last revised in**

January 2022

**PATIENT INFORMATION LEAFLET**

**MYALICA RANGE**

**9. Registration numbers**

MYALICA 25 mg: A49/2.5/0180

MYALICA 75 mg: A49/2.5/0182

MYALICA 150 mg: A49/2.5/0184